NCT04628429View on ClinicalTrials.gov

CGRP Inhibition, Autonomic Function, and Migraine

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Episodic MigraineChronic Migraine
Interventions
DRUG

Erenumab

anti-CGRP-receptor monoclonal anti-body

DRUG

Galcanezumab

anti-CGRP-ligand monoclonal anti-body

DRUG

Fremanezumab

anti-CGRP-ligand monoclonal anti-body

Trial Locations (1)

1090

RECRUITING

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER